10.08.2011 • News

Myriad Genetics Q4 Profit Falls

Myriad Genetics reported net income for the fourth quarter of $26.0 million or $0.30 per share, compared to $53.3 million or $0.54 per share for the year-ago quarter.

The latest quarter results include a $16.1 million income tax expense recorded for accounting purposes, while the year-ago quarter results included no tax expense and a one-time income tax benefit of $14.6 million.

Total revenue for the fourth quarter rose to $107.41 million from $93.93 million a year earlier.

Analysts polled by Thomson Reuters expected the company to earn $0.29 per share on revenue of $104.43 million for the fourth quarter.

For fiscal year 2012, the company forecast total revenue of $445 million to $465 million and earnings of $1.20 to $1.25 per share. Analysts currently expect the company to earn $1.26 per share on revenue of $453.80 million for the fiscal year 2012.

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read